Tokushima University / Educator and Researcher Directory --- Otani, Tamaki

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Bollos Christine Anne Leah Locsin, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Koji Yamaguchi, Tomomi Matsuura, Tamaki Otani, Takanori Bandoh, Yuya Ueki, Noritake Matsuda, Satoru Takashi, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis Secondary to Atrial Fibrillation Ablation, Asia Oceania Journal of Nuclear Medicine & Biology, Vol.13, No.1, 62-69, 2024. (Summary) We present two patients with a history of paroxysmal atrial fibrillation who developed pulmonary vein stenosis (PVS) following atrial fibrillation (AF) ablation. Case 1 involved a female patient in her 50s who was asymptomatic for pulmonary symptoms but was found to have a high degree of left superior PVS 15 months after AF ablation. This was demonstrated using contrast-enhanced computed tomography (CE-CT) and supported by findings of perfusion defects on ventilation-perfusion (V/Q) scan. Case 2 was a male patient in his 60s who developed progressive left superior PVS nine months after AF ablation, evidenced by serial CE-CT and V/Q scans. PVS is a rare but well-known complication of pulmonary vein ablation for the treatment of AF that can lead to severe complications if left untreated. V/Q scans effectively assess the functional significance of PVS by detecting abnormal blood flow segments. Although a V/Q mismatch characterized by reduced perfusion defects is more commonly used in evaluating pulmonary embolism, PVS should not be disregarded as a differential diagnosis. Few studies emphasize the utility of V/Q scans in managing PVS and highlight V/Q mismatch as a notable finding. This case report aimed to highlight their significance. (Link to Publication Site) ● Publication site (DOI): 10.22038/AOJNMB.2024.79650.1561 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.22038/AOJNMB.2024.79650.1561 (DOI: 10.22038/AOJNMB.2024.79650.1561)
2.	MATSUDA Noritake, Hideki Otsuka, Ryosuke Kasai, Tamaki Otani, BOLLOS CHRISTINE ANNE LEAH LOCSIN, Shota Azane, Yamato Kunikane, Youichi Otomi, UEKI Yuya, Mana Okabe, Masafumi Amano, Masanori Tamaki, Shu Wakino, Shoichiro Takao and Masafumi Harada : Quantitative evaluation of 67Gacitrate scintigraphy in the management of nephritis, Scientific Reports, Vol.14, No.16313, 16313, 2024. (Summary) In Ga-citrate scintigraphy (Ga-S), visual assessment is used by evaluating renal-uptake comparison with liver and spine and is simple and objective. We adopted the standardized uptake value (SUV) for Ga-citrate and proposed two quantitative indices, active nephritis volume (ANV) and total nephritis uptake (TNU). This study clarified the utility of new Ga-S-based quantitative indices in nephritis management. Before SUV measurement, the Becquerel calibration factor of Ga-citrate was obtained using a phantom experiment. Seventy patients who underwent SPECT/CT imaging were studied. SUV, ANV, and TNU were calculated using a quantitative analysis software for bone SPECT. SUV, ANV, and TNU were analyzed using the (1) threshold method (set 40%) and constant-value method for (2) vertebral SUV, and (3) vertebral SUV. ROC analysis was used to evaluate SUV, ANV, and TNU diagnostic abilities to distinguish nephritis presence and absence as well as interstitial nephritis (IN) and non-IN. The area under the curve (AUC) for nephritis presence or absence had a good value (0.80) for SUV (1), ANV (3), and TNU (3). The AUC for differentiation between IN and non-IN groups had a good value (0.80) for SUV (1). Thus, the new Ga-S-based quantitative indices were useful to evaluate nephritis and distinguish IN and non-IN. (Keyword) Humans / male / female / Middle Aged / Gallium Radioisotopes / Aged / Gallium / Adult / Nephritis / Citrates / ROC Curve / Aged, 80 and over / Radiopharmaceuticals / Single Photon Emission Computed Tomography Computed Tomography (Tokushima University Institutional Repository) ● Metadata: 119491 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-024-66823-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39009630 ● Search Scopus @ Elsevier (PMID): 39009630 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-024-66823-2 (Tokushima University Institutional Repository: 119491, DOI: 10.1038/s41598-024-66823-2, PubMed: 39009630)
3.	Yuya Ueki, Hideki Otsuka, Tamaki Otani, Ryosuke Kasai, Youichi Otomi, Daiki Ikemitsu, Shota Azane, Yamato Kunikane, Takanori Bandoh, Noritake Matsuda, Yasuyuki Okada, Tetsuji Takayama and Masafumi Harada : Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors, Japanese Journal of Radiology, Vol.42, No.5, 519-535, 2024. (Summary) Somatostatin receptor scintigraphy (SRS) using In-DTPA-DPhe-octreotide (pentetreotide) has become an integral part of neuroendocrine neoplasm management. The lack of precise quantification is a disadvantage of SRS. This study aimed to adapt the standardized uptake value (SUV) to SRS, establish the SUV range for physiological uptake in the liver, kidney, and spleen, and elucidate the utility of combined visual and quantitative SRS assessment for staging and restaging of neuroendocrine tumors (NETs). This study included 21 patients with NETs who underwent In-pentetreotide SRS. The SUV of physiological and pathological uptake was calculated using bone single-photon emission computed tomography (SPECT) quantitative analysis software (GI-BONE). For visual analysis, the primary and metastatic lesions were scored visually on planar and SPECT images using a five-point scale. We assessed the relationships between the SUVs of the liver, kidney, and spleen in the dual phase, and among quantitative indices, visual score, and pathological lesions classification. Sixty-three NEN lesions were evaluated. The mean ± standard deviation maximum SUVs (SUVmax) were liver: 4 h, 2.6 ± 1.0; 24 h, 2.2 ± 1.0; kidney: 4 h, 8.9 ± 1.8; 24 h, 7.0 ± 2.0; and spleen; 4 h, 11.3 ± 4.5; 24 h, 11.5 ± 7.6. Higher SUVmax was significantly associated with higher visual scores on dual-phase SPECT (4 h, p < 0.001; 24 h, p < 0.001) (4 h: scores 3 and 4, p < 0.05; scores 3 and 5: p < 0.01; scores 4 and 5: p < 0.01; 24 h: scores 3 and 4, p = 0.0748; scores 3 and 5: p < 0.01; scores 4 and 5: p < 0.01). We adapted the SUV to SRS and established the range of SUV for physiological uptake in the liver, kidney, and spleen. Combined visual and quantitative assessment is useful for imaging individual lesions in greater detail, and may serve as a new tumor marker of SRS for staging and restaging of NETs. (Keyword) Humans / Neuroendocrine Tumors / Male / Female / Middle Aged / Neoplasm Staging / Aged / Adult / Receptors, Somatostatin / Radiopharmaceuticals / Tomography, Emission-Computed, Single-Photon / Somatostatin / Retrospective Studies / Aged, 80 and over (Tokushima University Institutional Repository) ● Metadata: 118973 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-024-01529-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38345724 ● Search Scopus @ Elsevier (PMID): 38345724 ● Search Scopus @ Elsevier (DOI): 10.1007/s11604-024-01529-z (Tokushima University Institutional Repository: 118973, DOI: 10.1007/s11604-024-01529-z, PubMed: 38345724)
4.	Noritake Matsuda, Hideki Otsuka, Tamaki Otani, Shota Azane, Yamato Kunikane, Yoichi Otomi, Yuya Ueki, Masahiro Kubota, Masafumi Amano, Shusuke Yagi, Masataka Sata and Masafumi Harada : New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy, Japanese Journal of Radiology, Vol.41, No.4, 428-436, 2023. (Summary) Amyloid light chain (AL) and transthyretin (ATTR) are the major subtypes of cardiac amyloidosis (CA). Tc-pyrophosphate (PYP) scintigraphy is used to differentiate ATTR from other CA subtypes. We adapted the standardized uptake value (SUV) for Tc-PYP and proposed two quantitative indices, amyloid deposition volume (AmyDV) and total amyloid uptake (TAU). This study aimed to evaluate the utility of these quantitative indices in differentiating ATTR from non-ATTRs. Before the SUV measurement, the Becquerel calibration factor (BCF) of Tc was obtained by a phantom experiment. Thirty-two patients who had undergone hybrid SPECT/CT imaging 3 h after injection of Tc-PYP (370 MBq) were studied. CT attenuation correction for image reconstruction was applied in all. We calculated SUV, AmyDV, and TAU using a quantitative analysis software program for bone SPECT (GI-BONE) and analyzed AmyDV using two methods: threshold method (set 40%); and constant value method (average SUV of ribs). We assessed the diagnostic ability of heart-to-contralateral lung (H/CL) ratio, SUV, AmyDV, and TAU to differentiate ATTR from non-ATTR using receiver operating characteristic (ROC) analysis. Statistically significant differences in all quantitative indices were observed between ATTR and non-ATTR. The area under the curve of each quantitative index for discriminating between ATTR and non-ATTR were as follows: H/CL, 0.997; SUV, 0.953; SUV (M1), 0.964; SUV (M2), 0.969; AmyDV (M1), 0.875; AmyDV (M2), 0.974; and TAU, 0.974. The AmyDV (M2) had higher diagnostic ability than AmyDV (M1). Thus, TAU was calculated as AmyDV (M2) × SUV (M2). In the ROC curve, SUV, AmyDV, and TAU had almost the same diagnostic ability as H/CL in distinguishing ATTR from non-ATTRs. We propose two novel 3D-based quantitative parameters (AmyDV and TAU) that have almost equal ability to discriminate ATTR from non-ATTR. (Tokushima University Institutional Repository) ● Metadata: 117912 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11604-022-01364-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36449252 ● Summary page in Scopus @ Elsevier: 2-s2.0-85143121783 (Tokushima University Institutional Repository: 117912, DOI: 10.1007/s11604-022-01364-0, PubMed: 36449252, Elsevier: Scopus)
5.	Tamaki Otani, Hideki Otsuka, Kou Matsushita, Yoichi Otomi, Yamato Kunikane, Shota Azane, Masafumi Amano, Masafumi Harada and Hirokazu Miyoshi : Effect of different examination conditions on image quality and quantitative value of amyloid positron emission tomography using F-flutemetamol., Annals of Nuclear Medicine, Vol.35, No.9, 1004-1014, 2021. (Summary) The recommended start time for F-flutemetamol amyloid positron emission tomography (PET) examination is 60-120 min after F-flutemetamol injection, while an acquisition time of 10-30 min is generally recommended. We aimed to elucidate the effects of different examination conditions on image quality, diagnostic ability, and quantitative value of amyloid PET using F-flutemetamol. We acquired data on a Discovery PET/computed tomography 710 scanner using Hoffman brain and pillar phantoms with 20 MBq of F for 30 min. The images were reconstructed into 10-, 20-, and 30-min periods. The ordered subset-expectation maximization algorithm was used for image reconstruction, which uses a 2- or 4-mm Gaussian filter and a combination of iteration and subset numbers. The percentage contrast and coefficient of variation (CV; as the image noise) were used as physical evaluation indices for reconstructed images, and images with superior contrast and low image noise were selected for clinical evaluation. The imaging data of 15 symptomatic patients (n = 7 and n = 8 for positive and negative diagnoses of Alzheimer's disease, respectively) were reconstructed under the phantom study conditions. Radiographers visually evaluated and ranked the clinical images based on the overall contrast and image noise, and nuclear medicine specialists diagnosed Alzheimer's disease. We compared the standardized uptake value ratio (SUVR) obtained with different acquisition conditions. The basic study using the phantom revealed high convergence of contrast and image noise in five patterns of acquisition time and filter strengths. Regarding visual evaluation, the use of a 2-mm Gaussian filter caused difficulties in diagnosis because the brain parenchymal accumulation was mottled with high image noise. Differences in image quality and diagnostic ability due to different examination times were not significant. Differences in the SUVR were not significant in patients with a negative Alzheimer's disease diagnosis; in patients with a positive diagnosis, the SUVR showed significant fluctuation depending on the acquisition conditions. The differences in image quality and diagnostic performance due to the differences in 10-min acquisition time were not significant; however, of note, SUVR showed significant fluctuation depending on the acquisition conditions in patients diagnosed with Alzheimer's disease. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12149-021-01634-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34046870 ● Search Scopus @ Elsevier (PMID): 34046870 ● Search Scopus @ Elsevier (DOI): 10.1007/s12149-021-01634-3 (DOI: 10.1007/s12149-021-01634-3, PubMed: 34046870)
6.	Ryota Bando, Hideki Otsuka, Tamaki Otani, Noritake Matsuda, Shota Azane, Yamato Kunikane, Yoichi Otomi, Wataru Sako, Yuishin Izumi and Masafumi Harada : A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography., Annals of Nuclear Medicine, Vol.35, No.4, 504-513, 2021. (Summary) Dopamine transporter single-photon emission computed tomography (DAT SPECT) has been widely used to diagnose Parkinson syndrome. Using the standardized uptake value (SUV) of DAT SPECT, we propose "functional dopamine transporter volume (f-DTV)" as a new quantitative index to evaluate the three-dimensional volume of functional dopamine transporters and assess its diagnostic ability in differentiating dopaminergic neurodegenerative diseases (dNDD) from non-dNDD. Seventy-nine patients were enrolled (42 dNDD, 37 non-dNDD; 38 men; age 24-88 years). We analyzed seven quantitative indices. The specific binding ratio (SBR) was calculated using a program specialized for DAT SPECT (SBR_Bolt). The SUVmax, SUVpeak, and SUVmean were calculated using a quantification program for bone SPECT. SBR_SUV was calculated by dividing striatal SUVmean by the average of background SUVmean. The cutoff value of the active dopamine transporter level was examined using three methods (threshold of 40% of SUVmax, SUV 2, and SUV 3) to calculate the active dopamine transporter volume (ADV). The f-DTV was calculated by multiplying ADV and SUV. We assessed the correlations between SBR_Bolt and SBR_SUV, and compared the mean value of each index between the dNDD and non-dNDD groups. The abilities of SBR_Bolt, SBR_SUV, SUVmax, SUVpeak, SUVmean, ADV, and f-DTV in differentiating dNDD from non-dNDD were determined by the area under the receiver operating curve (AUC) generated by the receiver operating characteristics analysis. The SBR_Bolt and SBR_SUV highly correlated with each other (r = 0.71). The cutoff value of the active dopamine transporter level was determined as SUV 3. All seven quantitative indices showed lower values in the dNDD group than in the non-dNDD group, and the difference between the two groups was statistically significant (p < 0.05). Sensitivity, specificity, and AUC of f-DTV were slightly lower than those of SBR_Bolt (71%, 79%, and 0.81, respectively, for f-DTV, and 81%, 84%, 0.88, respectively, for SBR_Bolt). The difference in AUC between f-DTV and SBR_Bolt was not statistically significant. This study demonstrates the utility of f-DTV as a novel quantitative index for evaluating the three-dimensional volume of functional dopamine transporters, and that f-DTV has almost the same diagnostic ability to differentiate dNDD from non-dNDD using DAT SPECT. (Keyword) Adult / Aged / Aged, 80 and over / Biological Transport / Diagnosis, Differential / Dopamine Plasma Membrane Transport Proteins / female / Humans / Iodine Radioisotopes / male / Middle Aged / Nortropanes / Parkinson's disease / Phantoms, Imaging / ROC Curve / Retrospective Studies / Tomography, Emission-Computed, Single-Photon (Tokushima University Institutional Repository) ● Metadata: 115829 (Link to Publication Site) ● Publication site (DOI): 10.1007/s12149-021-01592-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33630226 ● Summary page in Scopus @ Elsevier: 2-s2.0-85101738030 (Tokushima University Institutional Repository: 115829, DOI: 10.1007/s12149-021-01592-w, PubMed: 33630226, Elsevier: Scopus)
7.	Yumiko Miyatake, Yuna Mishima, Rie Tsutsumi, Tamaki Otani, Naoya Suemasa, Saeko Masumoto, Masashi Kuroda and Hiroshi Sakaue : Assessment of insulin resistance in the skeletal muscle of mice using positron emission tomography/computed tomography imaging., Biochemical and Biophysical Research Communications, Vol.528, No.3, 499-505, 2020. (Summary) F]-fluoro-2-deoxy-D-glucose (FDG). FDG-PET/CT imaging revealed that insulin administration and exercise load significantly increased FDG accumulation in the skeletal muscle of C57BL/6J mice. FDG accumulation was lower in the skeletal muscle of 14-week-old db/db diabetic model mice exhibiting remarkable insulin resistance compared to that of 7-week-old db/db mice. Based on the continuous observation of FDG accumulation over time in diet-induced obese (DIO) mice, FDG accumulation significantly decreased in 17-week-old mice after the acquisition of insulin resistance. Although insulin-induced glucose uptake in the skeletal muscle was markedly attenuated in 20-week-old DIO mice that had already developed insulin resistance, exercise load effectively increased FDG uptake in the skeletal muscle. Thus, we successfully confirmed that glucose uptake accompanied by insulin administration and exercise load increased in the skeletal muscle using PET-CT. FDG-PET/CT might be an effective tool that could noninvasively capture the chronological changes of metabolic abnormalities in the skeletal muscle of mice. (Tokushima University Institutional Repository) ● Metadata: 118304 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrc.2020.05.165 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32513534 ● Search Scopus @ Elsevier (PMID): 32513534 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrc.2020.05.165 (Tokushima University Institutional Repository: 118304, DOI: 10.1016/j.bbrc.2020.05.165, PubMed: 32513534)
8.	Mariko Aoyama, Hiromitsu Takizawa, Tamaki Otani, Seiya Inoue, Naoya Kawakita, Mitsuhiro Tsuboi, Yoshimi Bando, Hisanori Uehara, Kazuya Kondo and Akira Tangoku : Noninvasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using smallanimal FDGPET/CT, Oncology Reports, Vol.44, 1709-1716, 2020. (Tokushima University Institutional Repository) ● Metadata: 115331 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2020.7720 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3892/or.2020.7720 (Tokushima University Institutional Repository: 115331, DOI: 10.3892/or.2020.7720)
9.	Tamaki Otani, Kazuya Kondo, Hiromitsu Takizawa, Koichiro Kajiura, Haruhiko Fujino, Hideki Otsuka and Hirokazu Miyoshi : Noninvasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDGPET/CT and CT., Oncology Reports, Vol.41, No.1, 447-454, 2019. (Summary) We established patient-like models of lung cancer metastasis by orthotopically implanting human non-small cell lung cancer cell lines into SCID mice. We evaluated the utilities of small-animal computed tomography (CT) and positron-emission tomography-computed tomography (PET/CT) in these models to non-invasively and repeatedly monitor the anticancer effects of cisplatin and erlotinib. We orthotopically implanted three non-small cell lung cancer cell lines, A549, FT821 and PC-9, into SCID mice. These mice were then divided into three groups: Control, cis-diamminedichloroplatinum (II) (CDDP) (7-mg/kg CDDP, single administration intraperitoneally), and erlotinib (25 mg/kg erlotinib/day, oral administration 5 days/week). After treatment initiation, we repeatedly performed PET/CT and CT measurements and assessed anticancer effects based on tumor volumes and FDG uptake. A549 tumors were not affected by CDDP or erlotinib. FT821 tumors were highly responsive to CDDP. PC-9 tumors, which have an epidermal growth factor receptor mutation, were highly responsive to erlotinib. Histological results and metastatic rates correlated with the anticancer effects shown by CT. In our orthotopic SCID mouse lung cancer models, 18FDG-PET/CT and CT imaging non-invasively and repeatedly monitored the efficacies of cisplatin and erlotinib against not only implanted tumors, but also mediastinal lymph node metastases. (Keyword) Animals / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Cisplatin / Erlotinib Hydrochloride / Fluorodeoxyglucose F18 / Humans / Lung Neoplasms / Lymph Nodes / Lymphatic Metastasis / male / Mice / Mice, SCID / Positron Emission Tomography Computed Tomography / Positron-Emission Tomography / Tomography, X-Ray Computed / Tumor Burden (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2018.6818 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30365151 ● Summary page in Scopus @ Elsevier: 2-s2.0-85056802482 (DOI: 10.3892/or.2018.6818, PubMed: 30365151, Elsevier: Scopus)
10.	Hirokazu Miyoshi, Mitsunori Hiroura, Kazunori Tsujimoto, Namiko Irikura, Tamaki Otani and Yasuo Shinohara : Preparation of new scintillation imaging material composed of scintillator-silica fine powders and its imaging of tritium, Radiation Protection Dosimetry, Vol.174, No.4, 478-484, 2017. (Summary) A new scintillation imaging material [scintillator-silica fine powder (FP)] was prepared using silica FPs and scintillator-encapsulating silica nanoparticles (NPs) (scintillator-silica NPs). The wt% values of scintillator-silica NPs on the scintillator-silica FPs were 38, 43, 36 and 44%. Scintillation images of 3H, 63Ni, 35S, 33P, 204Tl, 89Sr and 32P dropped on the scintillator-silica FPs were obtained at about 37 kBq per 0.1-10 µl with a charge-coupled device (CCD) imager for a 5 min exposure. In particular, high-intensity CCD images of 35S were selectively obtained using the 2.25, 4.77 and 10 µm silica FPs with scintillator-silica NPs owing to the residual S of dimethyl sulfoxide in the preparation. Scintillation images of 3H at 1670 ± 9 Bq/0.5 µl and 347 ± 6 Bq/0.5 µl dropped in a 2 mm hole on the scintillator-silica FPs (6.78 and 10 µm) were also obtained using the CCD imager for a 2 h exposure. (Link to Publication Site) ● Publication site (DOI): 10.1093/rpd/ncw251 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27664433 ● Search Scopus @ Elsevier (PMID): 27664433 ● Search Scopus @ Elsevier (DOI): 10.1093/rpd/ncw251 (DOI: 10.1093/rpd/ncw251, PubMed: 27664433)
11.	Hirokazu Miyoshi, Hitoshi Gotoh, Mitsunori Hiroura, Yusuke Yamanaka, Namiko Irikura, Tamaki Otani and Yuko Yamamoto : Enhancement of counting efciency for tritium using light-excited scintillator silica pellets, Journal of Radioanalytical and Nuclear Chemistry, Vol.311, No.3, 1991-1999, 2017. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10967-017-5185-2 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1007/s10967-017-5185-2 (DOI: 10.1007/s10967-017-5185-2)
12.	Koji Nakaya, Hideki Otsuka, Kazuya Kondo, Tamaki Otani and Motoi Nagata : Tumor growth-inhibitory effect of an angiotensin-converting enzyme inhibitor (captopril) in a lung cancer xenograft model analyzed using 18F-FDG-PET/CT., Nuclear Medicine Communications, Vol.37, No.2, 139-146, 2016. (Summary) We administered an angiotensin-converting enzyme inhibitor (captopril) to mice implanted with a human lung adenocarcinoma epithelial cell line (A549 cells) and investigated the tumor growth-inhibitory effect of captopril from the viewpoint of glucose metabolism using (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/CT. Subcutaneous implantation of A549 cells (1.9×10(6) cells) was carried out in the lower right flank of mice. Fifteen days after the transplantation of A549 cells, mice (six in each group) were treated with captopril (3.0 mg/mouse) or saline (1000 μl/mouse) for 5 days. We performed (18)F-FDG-PET/CT imaging of the mice before and after the treatment and evaluated the degree of (18)F-FDG accumulation in tumors. In both groups (the captopril-administrated and control groups), values for the metabolic tumor volume (MTV), maximum standardized uptake value, total lesion glycolysis, and tumor volume after treatment had a tendency to increase. However, tumor growth was suppressed in the captopril-administrated group compared with the control group. In terms of the growth rate, the MTV and tumor volume were significantly different (P<0.05). It was found that captopril exerted a potential tumor growth-inhibitory effect; this was because the captopril-administrated group showed low values of MTV, maximum standardized uptake value, total lesion glycolysis, and tumor volume in comparison with the control group. (Link to Publication Site) ● Publication site (DOI): 10.1097/MNM.0000000000000404 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26465803 ● Summary page in Scopus @ Elsevier: 2-s2.0-84953361815 (DOI: 10.1097/MNM.0000000000000404, PubMed: 26465803, Elsevier: Scopus)
13.	Maerjianghan Abuduli, Hirokazu Ohminami, Tamaki Otani, Hitoshi Kubo, Haruka Ueda, Yoshichika Kawai, Masashi Masuda, Hisami Okumura, Hiroshi Sakaue, Hironori Yamamoto, Eiji Takeda and Yutaka Taketani : Effects of dietary phosphate on glucose and lipid metabolism., American Journal of Physiology, Endocrinology and Metabolism, Vol.310, No.7, E526-E538, 2016. (Summary) Recent epidemiological and animal studies have suggested that excess intake of phosphate (Pi) is a risk factor for the progression of chronic kidney disease and its cardiovascular complications. However, little is known about the impact of dietary high Pi intake on the development of metabolic disorders such as obesity and type II diabetes. In this study, we investigated the effects of dietary Pi on glucose and lipid metabolism in healthy rats. Male, 8-wk-old Sprague-Dawley rats were divided into 3 groups and given experimental diets containing varying amounts of Pi, i.e. 0.2% (low Pi, LP), 0.6% (control Pi, CP), and 1.2% (high Pi, HP). After 4 weeks, HP group showed lower visceral fat accumulation compared with other groups, accompanied by a low respiratory exchange ratio (VCO2/VO2) without alteration of locomotive activity. HP group had lower levels of plasma insulin and non-esterified fatty acids. In addition, HP group also showed suppressed expression of hepatic lipogenic genes including sterol regulatory element binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase, whereas there was no difference in hepatic fat oxidation among the groups. On the other hand, uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator alpha (PGC1) expression were significantly increased in the brown adipose tissue (BAT) of HP group. Our data demonstrated that a high Pi diet can negatively regulate lipid synthesis in the liver, and increased mRNA expression related to lipid oxidation and UCP1 in BAT, thereby preventing visceral fat accumulation. Thus, dietary Pi is a novel metabolic regulator. (Tokushima University Institutional Repository) ● Metadata: 109976 (Link to Publication Site) ● Publication site (DOI): 10.1152/ajpendo.00234.2015 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26786774 ● Search Scopus @ Elsevier (PMID): 26786774 ● Search Scopus @ Elsevier (DOI): 10.1152/ajpendo.00234.2015 (Tokushima University Institutional Repository: 109976, DOI: 10.1152/ajpendo.00234.2015, PubMed: 26786774)
14.	Tamaki Otani, Hideki Otsuka, Kazuya Kondo, Hiromitsu Takizawa, Motoi Nagata, Mina Kishida and Hirokazu Miyoshi : Utility of respiratory-gated small-animal PET/CT in the chronologic evaluation of an orthotopic lung cancer transplantation mouse model., Radiological Physics and Technology, Vol.8, No.2, 266-277, 2015. (Summary) Our aim in this study was to clarify the effects of respiratory-gated PET in the evaluation of lung cancer according to the (18)F-FDG uptake in an orthotopic transplantation mouse model. We created such a model, and we performed PET/CT. The mice were divided into two groups according to tumor volume: a small-tumor group (<20 mm(3)) and a large-tumor group (>20 mm(3)). We reconstructed the following conditions based on list-mode data: non-gated (3D) images and gated (4D) images, divided based on the respiratory cycle (expiration phase, stable phase, and inspiration phase). We calculated the maximum standardized uptake values (SUVmax) in each phase. We used the % difference [= (4D SUVmax - 3D SUVmax)/3D PET SUVmax × 100 (%)] to evaluate the differences in the 4D SUVmax and 3D SUVmax. The 4D SUVmax values were significantly higher than the 3D SUVmax, regardless of the tumor size. The % difference for the small tumors was greater than that for the large tumors, and it was highest in the stable phase. We conclude that the SUVmax in the stable phase under respiratory-gated PET are the most reliable. The SUVmax observed under non-gated PET are considered to be more frequently underestimated in cases involving small tumors than in those involving large tumors. In the chronologic study evaluating the time course of tumor development, the size of the tumor is small in early stage, and respiratory-gated PET is effective in reducing the underestimation of such tumors caused by respiratory motion. (Tokushima University Institutional Repository) ● Metadata: 109701 (Link to Publication Site) ● Publication site (DOI): 10.1007/s12194-015-0316-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25921487 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937518832 (Tokushima University Institutional Repository: 109701, DOI: 10.1007/s12194-015-0316-3, PubMed: 25921487, Elsevier: Scopus)
15.	Hirokazu Miyoshi, Tamaki Otani and Namiko Irikura : In situ 18F-gamma-ray induced Ag nanoparticle formation in the presence of SiO2 nanoparticles under air, Journal of Radioanalytical and Nuclear Chemistry, Vol.302, No.3, 1177-1183, 2014. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10967-014-3359-8 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-84919413696 (DOI: 10.1007/s10967-014-3359-8, Elsevier: Scopus)
16.	Mohamed Mokhtar, Kazuya Kondo, Hiromitsu Takizawa, Tamaki Otani, Hideki Otsuka, Hitoshi Kubo, Koichiro Kajiura, Yasushi Nakagawa, Yukikiyo Kawakami, Mitsuteru Yoshida, Haruhiko Fujino, Shoji Sakiyama and Akira Tangoku : Non-invasive monitoring of anticancer effects of cisplatin on lung cancer in an orthotopic SCID mouse model using [¹⁸F] FDG PET-CT., Oncology Reports, Vol.31, No.5, 2007-2014, 2014. (Summary) Positron emission tomography-computed tomography (PET-CT) with [18F] fluorodeoxyglucose (FDG) has recently been applied for evaluating tumor response to anticancer therapy. The aim of the present study was to evaluate the utility of FDG PET-CT in monitoring non-invasively and repeatedly the inhibitory effect of cisplatin (CDDP) on an orthotopic lung cancer model. Validation of in vivo FDG uptake in human lung cancer Ma44-3 cell line in an orthotopic SCID mouse model was carried out. Next, we assessed the use of FDG PET-CT to monitor the response of orthotopic lung cancer to the anticancer effect of CDDP. SCID mice were divided into the CDDP group (7 mg/kg single dose intraperitoneally) and the control group. Tumor volume and maximal standardized uptake value (SUV max) were calculated for all mice. All mice were sacrificed for histopathologic analysis. Validation of FDG PET-CT showed that tumor volume and SUV max were significantly correlated with postmortem tumor length measured in specimens (P=0.023) and (P=0.012), respectively, and there was a significant correlation between SUV max and tumor volume (P=0.048). Response monitoring showed that significant growth inhibition by CDDP in the form of SUV max of the CDDP group was significantly lower than that of the control group on day 8 (P=0.02) and on day 13 (P=0.003). Tumor volume of the CDDP group was significantly lower than that of the control group on day 13 (P=0.03). The present study supports using FDG PET-CT in monitoring tumor progression and therapeutic response of lung cancer in an orthotopic model non‑invasively and repeatedly. (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2014.3056 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24604559 ● Summary page in Scopus @ Elsevier: 2-s2.0-84898640682 (DOI: 10.3892/or.2014.3056, PubMed: 24604559, Elsevier: Scopus)
17.	Hitoshi Kubo, Tamaki Otani, Hideki Otsuka and Masafumi Harada : The impact of self-shielded cyclotron operation on small-animal PET/CT equipment installed nearby, on the floor just above., The Journal of Medical Investigation : JMI, Vol.61, No.1-2, 46-52, 2014. (Summary) The purpose of this study was to evaluate the impact of a cyclotron on small-animal PET equipment installed directly above the cyclotron. The cyclotron equipment was HM-12, which has two targets, and the PET/CT equipment was Inveon. The equipment was installed in conformity to Japanese law and regulations. Before installation of the PET/CT equipment, the radiation dose, radio waves, and static and fluctuating magnetic fields were measured at the position where it would be placed, both when the cyclotron was in use and when it was not in use. After installation of the PET/CT, natural background and emission counts were measured at the same place under the same conditions. An increase of radiation dose was observed when the target nearest the PET equipment was used. There were no distinct effects of radio waves or static and fluctuating magnetic fields. A significant increase of emission counts, approximately 300 cpm, was observed when the nearest target was used. Though radio waves and static and fluctuating magnetic fields generated by running cyclotron had no influence, a significant increase in emission count was observed. Careful attention should be paid to this influence when very low-radioactivity PET measurements are done. (Keyword) Animals / Cyclotrons / Equipment Failure / Japan / Magnetic Fields / Positron-Emission Tomography / Radiation Dosage / Radio Waves / Static Electricity / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 109516 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.61.46 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24705748 ● Search Scopus @ Elsevier (PMID): 24705748 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.61.46 (Tokushima University Institutional Repository: 109516, DOI: 10.2152/jmi.61.46, PubMed: 24705748)

Proceeding of International Conference:

1.	Tamaki Otani, Hitoshi Ikushima, Yoshimi Bando, Kenmei Kuwahara, Hideki Otsuka, Kazuya Kondo and Hirokazu Miyoshi : Efficacy of 18F-fluorothymidine and 18F-fluorodeoxyglucose Positron Emission Tomography in Determining a Radiotherapy Effect., Annual Congress of the European Association of Nuclear Medicine, Oct. 2021.
2.	Tamaki Otani, Hideki Otsuka, Koh Matsushita, 音見陽一, Yamato Kunikane, Shota Azane and Hirokazu Miyoshi : Possibility of Shortening Examination Time in Amyloid PET using 18F-Flutemetamol., Society of Nuclear Medicine and Molecular Imaging 2020 annual meeting, Jul. 2020.
3.	Tamaki Otani, Kazuya Kondo, Hiromitsu Takizawa, Koichiro Kajiura, Fujino Haruhiko and Hideki Otsuka : Non-Invasive Assessment of Cisplatin and Erlotinib Efficacy in Lung Cancer by Monitoring an Orthotopic SCID Mouse Model with Computed Tomography, 16th World Conference on Lung Cancer, Sep. 2015.
4.	Hiromitsu Takizawa, Kazuya Kondo, Mitsuhiro Tsuboi, Koichiro Kajiura, Tamaki Otani, Hiroaki Toba, Yukikiyo Kawakami, Shoji Sakiyama and Akira Tangoku : Mini OralComputed Tomography Lymphography by Transbronchial Injection of Iopamidol for Preoperative, 16th World Conference on Lung Cancer, Sep. 2015.
5.	Abuduli Maerjianghan, Ohminami Hirokazu, Tamaki Otani, Kubo Hiroshi, Ueda Haruka, Eiji Takeda and Yutaka Taketani : Effect of Dietary Phosphate on Glucose Metabolism by 18F-FDG PET/CT in Rats, 75th Scientific Sessions, American Diabetes Association, Boston Convenstion and Exhibition Center, Boston MA, June 5-9, 2015, Jun. 2015.
6.	Hirokazu Miyoshi, Mitsunori Hiroura, Kazunori Tshuji, Namiko Irikura and Tamaki Otani : Newscintillation imaging material composed of fine silica powder for tritium detection, 15th International Congress of Radiation Research (ICRR 2015), Kyoto, May 2015.
7.	Tamaki Otani, Hideki Otsuka, Kazuya Kondo, Hiromitsu Takizawa and Nagata Motoi : Utility of respiratory-gated PET/CT in the chronological evaluation of an orthotopic lung cancer transplantation mouse model, Annual Congress of the European Association of Nuclear Medicine, Oct. 2014.

Proceeding of Domestic Conference:

1.	Youichi Otomi, Takanori BANDOH, Hideki Otsuka, Ryosuke Kasai, Tamaki Otani, Yamato Kunikane, 岡田直子, Tomoki MATSUSHITA, Takashi Kawanaka, Takayoshi Shinya and Masafumi Harada : Clinical practice of peptide receptor radionuclide therapy in Tokushima University Hospital, 第64回日本核医学会学術総会/第44回日本核医学技術学会総会学術大会, Nov. 2024.
2.	MATSUDA Noritake, Ryosuke Kasai, Hideki Otsuka, Tamaki Otani, Satoru Takashi and Yamato Kunikane : 最適輸送理論を用いたSPECT/CT における減弱補正の検討, 第20回中四国放射線医療技術フォーラム CSFRT2024, Oct. 2024.
3.	板東孝典, Youichi Otomi, Ryosuke Kasai, Tamaki Otani, MATSUDA Noritake, Takayoshi Shinya, Yamato Kunikane, Shota Azane, Hideki Otsuka and Masafumi Harada : 123I-MIBGを用いた副腎髄質シンチグラフィ定量評価の試み, 第5回日本核医学会中国・四国支部会, Jul. 2024.
4.	MATSUDA Noritake, Ryosuke Kasai, Hideki Otsuka, Tamaki Otani and Yamato Kunikane : 最適輸送理論による減弱補正の初期検討, 日本核医学技術学会, Jun. 2024. (Summary) 【目的】 CTAC(CTbasedattenuationcorrection)は核医学領域で最も一般的に利用されている補正法であるが，CT 撮影による被ばくの問題がある.近年，深層学習を使用した減弱補正法も考案されているが，学習に必要なデータセット作成の課題や，学習・実装のコストから問題点も多い.そこで，減弱補正に最適輸送理論に基づくドメイン適応を応用し，最適輸送減弱補正(OTAC: optimal transportAC) 法を提案する.最適輸送は確率分布を比較するツールとして知られ，機械学習の評価関数として広く利用されている.OTAC では，CTAC による補正後の一対の画像から，色相変換の手続きにより，補正後のドメインに適応し，マッピング推定を行う.すなわち，最適輸送による原理を用いることで，二つの画像のピクセルの対応関係を介した色相変換により，画像の形態は保持したまま，最適な画素値へのマッピングの実現が期待できる.本研究の目的は， OTAC を提案すること，およびその有効性を確認することである. 【方法】 99mTc を封入した円柱ファントムの SPECT 画像の CTAC による補正前後の画像ペアを用いた.最適輸送を使用し，輸送元の各ピクセルを輸送先の画素値に輸送コストの最小化によるマッピングをすることで，画素値の差の総和が最小になるように変換した.得られた最適輸送による減弱補正(OTAC)画像と CTAC 画像の視覚および，取得画像の濃度プロファイルによって提案法の性能評価を行った. 【結果】視覚的な結果および濃度プロファイルの結果から，OTAC は CTAC と同程度の性能を有していることが分かった. 【結論】最適輸送を用いた減弱補正を提案し，円柱ファントム画像において CTAC と同程度の結果が得られた.本手法では，減弱補正のための CT 撮影が不要であり，被曝低減を導くことができる.さらに深層学習のような大量の学習画像や実装コストも不要であり，結果も深層学習より高速に得られた.
5.	BANDOH Takanori, Ryosuke Kasai, Tamaki Otani, NAGAO Sana, MATSUDA Noritake, Satoru Takashi, Shota Azane and Hideki Otsuka : Attempt at quantitative evaluation using lutetium scintigraphy after peptide receptor radionuclide therapy, 第80回日本放射線技術学会総会学術大会, Apr. 2024.
6.	BOLLOS CHRISTINE ANNE LEAH LOCSIN, Ryosuke Kasai, Hideki Otsuka, Youichi Otomi, Tomomi Matsuura, Tamaki Otani, BANDOH Takanori, UEKI Yuya, MATSUDA Noritake, 高志智, Shota Azane, Yamato Kunikane, Shoichiro Takao, Shusuke Yagi, Masataka Sata, Hitoshi Ikushima and Masafumi Harada : Ventilation/Perfusion Mismatch in Pulmonary Vein Stenosis After Atrial Fibrillation Ablation, 第268回徳島医学会学術集会, Mar. 2024.
7.	KAWABATA Yuka, Ryosuke Kasai, Tamaki Otani, Takanori Bandoh, NORITAKE Matsuda, Shota Azane, Satoru Takashi, Yamato Kunikane, Masafumi Amano and Hideki Otsuka : 心臓サルコイドーシスを対象とした画像検査 ∼ 18F-FDG PET の有用性を中心に∼, 第19回中四国放射線医療技術フォーラム CSFRT2023, Nov. 2023.
8.	Tamaki Otani, Hirokazu Miyoshi, Yamato Kunikane and Shota Azane : 陽電子断層撮像装置の経年変化による定量性変動, 第4回日本保健物理学会・放射線安全管理学会合同大会, Nov. 2022.
9.	KAJINO Akimi, Hitoshi Ikushima, Motoharu Sasaki, Tamaki Otani, Michiko Yamashita and Akihiro Haga : 放射線治療効果を早期に検出できるRadiomics特徴量の探索, 日本放射線腫瘍学会第35回学術大会, Nov. 2022.
10.	Hirokazu Miyoshi, Mami Nakamura, Tamaki Otani and Hideaki Horikawa : シンチレーションペーパーの放射能測定紙としての応用, 第3回日本放射線安全管理学会・日本保健物理学会合同大会Web開催, Dec. 2021.
11.	Hitoshi Ikushima, Tamaki Otani, Hideki Otsuka, Takashi Kawanaka, Akiko Kubo and 外磯千智 : 放射線治療における18F-3'-deoxy-3'-fluorothymidine の有用性, 第134回日本医学放射線学会中国四国地方会, Jun. 2021.
12.	MISHIMA Yuna, Rie Tsutsumi, Tamaki Otani, Kanako Hara, Saori Fujimoto, Masashi Kuroda and Hiroshi Sakaue : PET/CTを用いたマウス骨格筋インスリン抵抗性の評価, 第41回日本肥満学会, Mar. 2021.
13.	Hideaki Horikawa, Yoshinori Kuwahara, 合田康代, 安井栄梨, Tamaki Otani and Hirokazu Miyoshi : 非密封放射性同位元素の使用施設におけるより良い放射線安全管理の追求, 第19回日本放射線安全管理学会学術大会(Web開催), Dec. 2020.
14.	三島優奈, Rie Tsutsumi, Masashi Kuroda, Hiroshi Sakaue and Tamaki Otani : PET/CTを用いたマウス骨格筋インスリン抵抗性の評価, Shikoku Acta Medica, Vol.76, No.5-6, 342, Dec. 2020. (Keyword) インスリン抵抗性(実験的) 骨格筋(X線診断,放射性核種診断) *PET-CT検査マウス動物
15.	Tamaki Otani, Hitoshi Ikushima, Yoshimi Bando, Hideki Otsuka, Kazuya Kondo and Hirokazu Miyoshi : 放射線治療効果判定における18F-FLT PETの有効性の検討, 第60回日本核医学学術総会, Nov. 2020.
16.	Mitsuteru Yoshida, Kazuya Kondo, Tamaki Otani, Hirohisa Ogawa, Naoki Miyamoto, 竹原恵美, Mika Takashima, Daisuke Matsumoto, Naoya Kawakita, Mitsuhiro Tsuboi, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa and Akira Tangoku : 呼吸器外科の癌免疫療法研究-CMT167マウス肺癌細胞株同所移植モデルマウスの確立に向けて-, 第37回日本呼吸器外科学会学術集会(Web開催), Sep. 2020.
17.	徳里望, Hiroshi Sakaue, Rie Tsutsumi, Masashi Kuroda, Saeko Masumoto, 原加奈子, Rie Tsutsumi, 三島優奈, 松本裕華, Masashi Kuroda, Tamaki Otani and Hiroshi Sakaue : PET/CTを用いた代謝性疾患モデルマウス骨格筋糖取り込みの評価, Journal of the The Japan Diabetes Society, Vol.63, No.9, 649, Sep. 2020. (Keyword) Catechin 肥満(実験的) Biflavonoids Proanthocyanidins 認知機能低下(実験的) 消化管微生物叢 Procyanidin マウス動物 / 高インスリン症(実験的) 疾患モデル(動物) 骨格筋(X線診断,放射性核種診断) Fluorodeoxyglucose F18(診断的利用) PET-CT検査マウス動物オス
18.	Tamaki Otani, Hideki Otsuka, Yamato Kunikane, Shota Azane, 藤田明彦, Masafumi Amano, 福永有希子 and Hirokazu Miyoshi : PET, 第76回日本放射線技術学会総会学術大会, May 2020.
19.	徳里望, Hiroshi Sakaue, Rie Tsutsumi, Masashi Kuroda, Saeko Masumoto, 三島優奈, Rie Tsutsumi, 松本裕華, 原加奈子, Tamaki Otani, 上嶋菜々子, 神田彩恵, Masashi Kuroda and Hiroshi Sakaue : 廃用性筋萎縮モデルにおける骨格筋・肝代謝動態の連関による生体機能制御, The Journal of Metabolism and Clinical Nutrition, Vol.23, No.Suppl., S-54, Jan. 2020. (Keyword) Catechin 肥満(実験的) Biflavonoids Proanthocyanidins 認知機能低下(実験的) 消化管微生物叢 Procyanidin マウス動物 / 遺伝子発現エネルギー代謝筋萎縮症(実験的) 骨格筋糖代謝廃用症候群(実験的) Large Neutral Amino Acid-Transporter 1 マウス動物
20.	MISHIMA Yuna, Rie Tsutsumi, Yuka Matsumoto, Kanako Hara, Tamaki Otani, Nanako Ueshima, 神田彩恵, Masashi Kuroda and Hiroshi Sakaue : 廃用性筋萎縮モデルにおける骨格筋・艦隊者動態の連関による生体機能制御, 第23回日本病態栄養学会年次学術集会, Jan. 2020.
21.	Hirokazu Miyoshi, Tamaki Otani, Yoshinori Kuwahara, Hideaki Horikawa, 合田康代 and 安井栄梨 : 学内の放射線安全管理体制についての考察, 第2回放射線安全管理学会・日本保健物理学会合同大会, Dec. 2019.
22.	Tamaki Otani, 草壁翔太, Hirokazu Miyoshi and Yamato Kunikane : サイクロトロン施設における標識合成設備と排気放射能濃度の関係, 第2回放射線安全管理学会・日本保健物理学会合同大会, Dec. 2019.
23.	Hirokazu Miyoshi, 湯本明, 中村真美, 伊月義則, 吉岡歩美 and Tamaki Otani : シンチレーションペーパーのふき取り効率, 第2回日本放射線安全管理学会・日本保健物理学会合同大会, Dec. 2019.
24.	MISHIMA Yuna, Rie Tsutsumi, Yumiko Miyatake, Naoya Suemasa, Tamaki Otani, Naoko Kodama, Yohsuke Tamba, Masashi Kuroda, Saeko Masumoto and Hiroshi Sakaue : PET/CTを用いた代謝異常時の骨格筋における糖取り込みの測定, 第62回日本糖尿病学会, May 2019.
25.	Tamaki Otani, Hirokazu Miyoshi and 草壁翔太 : 自己遮蔽型サイクロトロンの運転時間と放射化物の関係性, 日本放射線安全管理学会第17回学術大会, Dec. 2018.
26.	Tamaki Otani, Hideki Otsuka, Yamato Kunikane, 高志智, 板東良太, 藤田明彦, Masafumi Amano, 福永有希子, Shota Azane and Hirokazu Miyoshi : 2. Ra-223イメージングにおける最適測定条件の検討, 第38回日本核医学技術学会総会学術大会, Nov. 2018.
27.	Tamaki Otani, Hirokazu Miyoshi, 藤田明彦, Masafumi Amano, Yamato Kunikane, 福永有希子, 高志智 and 坂東良太 : 放射線検出モジュールC12137を用いたRa-223γ(X)線スペクトル解析, 日本放射線安全管理学会第16回学術大会, Jun. 2017.
28.	Tomohiko Kuwabara, Hirokazu Miyoshi, Yoko Yamashita, Tokue Kuroda, Namiko Irikura, Yoshinori Kuwahara, 安井栄梨, 合田康代 and Tamaki Otani : RI施設の排風量を担保するための簡易風量計によるドラフト風量随時測定法の検討, 日本放射線安全管理学会第16回学術大会, Jun. 2017.
29.	Hirokazu Miyoshi, Mami Nakamura, 合田康代, 安井栄梨, Tamaki Otani, Namiko Irikura and Yoshinori Kuwahara : 放射線業務従事者の放射線安全の理解度とヒヤリとした事例の分析, 日本放射線安全管理学会第15回学術大会(岡山大学), Dec. 2016.
30.	Yoko Yamashita, Tokue Kuroda, Tomohiko Kuwabara, Namiko Irikura, 安井栄梨, Yoshinori Kuwahara, 合田康代, Tamaki Otani and Hirokazu Miyoshi : 非密封RI施設における排気時間の再考, 日本放射線安全管理学会第15回学術大会(岡山大学), Dec. 2016.
31.	Tamaki Otani, Hideki Otsuka, Hirokazu Miyoshi, Yoshinori Kuwahara and Namiko Irikura : 動物PET計測において遮蔽体が散乱係数に与える影響, 日本放射線安全管理学会第15回学術大会(岡山大学), Dec. 2016.
32.	Tokue Kuroda, Yoko Yamashita, Tomohiko Kuwabara, Namiko Irikura, 安井栄梨, Yoshinori Kuwahara, 合田康代, Tamaki Otani and Hirokazu Miyoshi : RI施設管理の自己点検評価への新しい試み, 平成28年度放射線安全取扱部会年次大会(鎌倉), Nov. 2016.
33.	Hirokazu Miyoshi, Masayuki Shono and Tamaki Otani : 5-FU-マルトールナノ粒子複合体の5-FU放出機構, 2016年日本化学会中国四国支部大会, 72, Nov. 2016.
34.	Hirokazu Miyoshi, Masayuki Shono, shingo Imagawa, Tamaki Otani, Masashi Kurashina and Eiji Kanezaki : 細胞膜吸着性と徐放出性を有する新規マルトール-シリカナノ粒子複合体の調製, 2015日本化学会中国四国支部大会, Nov. 2015.
35.	Abuduli Maerjianghan, 大南博和, Hiroshi Sakaue, Tamaki Otani, 上田遥香, Eiji Takeda and Yutaka Taketani : 食事性のリンが糖代謝に及ぼす影響:PET/CT用いた解析, 第36回日本肥満学会，名古屋国際会議場，愛知県名古屋市，2015年10月2日~3日, Oct. 2015.
36.	Hirokazu Miyoshi, Tamaki Otani, Yoshinori Kuwahara, Namiko Irikura, 合田康代, 安井栄梨 and 永田基 : 放射線教育スライドのパッケージ化とその効果, 日本放射線安全管理学会第13回学術大会, 151, Dec. 2014.
37.	Tamaki Otani, Hirokazu Miyoshi, 永田基 and Hideki Otsuka : Daily-QCから得られる物理的指標値からみるPET装置の経年変化, 日本放射線安全管理学会第13回学術大会, 128, Dec. 2014.
38.	Tamaki Otani, Hideki Otsuka and 永田基 : 肺癌同所移植モデルマウスの呼吸同期PET/CT測定の有用性の検討, 第54回日本核医学学術総会, Nov. 2014.
39.	Hirokazu Miyoshi, Tamaki Otani, 永田基 and Namiko Irikura : 18-Fを用いたシリカナノ粒子水分散液における放射線化学反応の試み, 日本放射線安全管理学会第12回学術大会, Nov. 2013.
40.	Hirokazu Miyoshi, 安井栄梨, Namiko Irikura, Tamaki Otani and 永田基 : 土壌中の放射性セシウムの加水による放射能分布変化とその分析, 日本放射線安全管理学会第12回学術大会, Nov. 2013.
41.	Tamaki Otani, Hideki Otsuka, Kazuya Kondo, Hiromitsu Takizawa and Hirokazu Miyoshi : 肺癌同所移植モデルマウスの18F-FDG PET/CTイメージング, 日本放射線安全管理学会第12回学術大会, Nov. 2013.
42.	Hiromitsu Takizawa, Kazuya Kondo, Tamaki Otani, Hideki Otsuka, Mitsuhiro Tsuboi, Koichiro Kajiura, Yasushi Nakagawa, Mitsuteru Yoshida, Yukikiyo Kawakami, Shoji Sakiyama and Akira Tangoku : PET/CTによるヒト肺癌細胞株肺移植モデルマウスの腫瘍評価, 第54回日本肺癌学会総会, Nov. 2013.
43.	岸田弥奈, Tamaki Otani, Hideki Otsuka and Kazuya Kondo : 肺癌同所移植モデルマウスの経時的測定におけるPET呼吸同期収集がSUVに与える影響について, 中四国放射線技術ファーラム2013, Nov. 2013.
44.	Tamaki Otani and Hideki Otsuka : 動物用PET/CTを用いた乳癌骨転移モデルマウスのゾレドロン酸による治療効果評価法の検討, 第53回日本核医学学術総会, Nov. 2013.

Et cetera, Workshop:

1.	Tsuyoshi Tahara, Chiho Shonozaki, Tetsuro Yoshimaru, 毛利浩太, Masaya Denda, Tamaki Otani, Toyomasa Katagiri, Akira Otaka, 向井英史 and 崔翼龍 : Kinetic analysis for lapidated anti-cancer peptides using PET, 日本分子イメージング学会, May 2024.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Novel Cancer Treatment Strategies Based on Radiomics Imaging Analysis (Project/Area Number: 23K07158 )
Food additives inhibit or accelerate the transfer of radionuclides in a body (Project/Area Number: 23K22215 )
Molecular Imaging Radiomics Model for Prediction of Radiotherapy Effect (Project/Area Number: 20K07698 )
Prediction of erlotinib antitumor effect using 11C-Erlotinib (Project/Area Number: 15K19797 )
Search by Researcher Number (40709557)

Assistant Professor : Otani, Tamaki

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)